BY THE NUMBERS.
WHERE IT LANDED.
HOW FULL THE BUS GOT.
TICKET CLASSES.
HOW THE ISSUE IS BUILT.
The two legs send the money to different places: a fresh issue raises new capital for the company, while an offer for sale is existing shares being sold by existing shareholders, whose proceeds go to those sellers and not to the company.
ON THE DASHBOARD.
THE RUNNING RECORD.
WHO ELSE RUNS THIS LINE.
Notes: P/E Ratio has been computed based on the closing market price of equity shares on August 17, 2026, divided by the diluted EPS. Return on Net Worth is calculated as profit for the year attributable to owners of the parent company divided by the Net Worth as at the end of the respective year. Net Asset Value per share is calculated as Net Worth as at year divided by the number of Equity Shares outstanding as at the end of the year. For Cohance Lifesciences Limited, RoNW for Financial Year 2026 is calculated as Adjusted PAT / average shareholder's funds as stated in the investor presentation. For Laurus Labs Limited, RoNW for Financial Year 2026 is calculated as PAT/ (equity + reserves) as stated in their annual report.
WHAT THE MONEY IS FOR.
WHO GETS WHICH SEATS.
Symbiotec Pharmalab Ltd. is an integrated pharmaceutical and biotechnology company focused on the research, development, and manufacturing of active pharmaceutical ingredients (APIs), nutraceutical ingredients, and specialty healthcare products. The company serves customers across both regulated and emerging international markets, supplying products to the pharmaceutical, nutraceutical, and wellness sectors. The company combines scientific expertise, stringent quality standards, and sustainable manufacturing practices to deliver innovative and high-quality ingredients that meet global regulatory requirements. Through its research-oriented approach, Symbiotec continues to expand its product portfolio and strengthen its presence in international markets. With more than three decades of industry experience, Symbiotec has transformed from a laboratory-scale manufacturer of steroidal-hormone APIs in 1995 into a large-scale, backward-integrated manufacturing platform. The company has obtained approvals and certifications from major global regulatory authorities, including the US FDA, EU-GMP, the Ministry of Food and Drug Safety (South Korea), and several other international agencies. As of June 30, 2025, Symbiotec operated two industrial-scale API manufacturing facilities with a combined chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres (KL). Key Strengths: Established position among the leading manufacturers of corticosteroid and steroidal-hormone APIs globally. Strong and enduring relationships with a diversified domestic and international customer base. Vertically integrated, multi-scale manufacturing infrastructure supported by sustainable operations and a strong regulatory compliance record. Consistent investment in research and development, supported by advanced technological capabilities. Ability to expand into new market opportunities through scientific innovation, process expertise, and intellectual property-driven product development.
ON THE ROSTER.
COMMON QUESTIONS.
What is the Symbiotec Pharmalab IPO price band?+
The indicative price band is ₹988 per share. The binding terms are the ones in the Red Herring Prospectus (RHP).
What is the lot size of the Symbiotec Pharmalab IPO?+
One lot is 15 shares. At the upper band of ₹988, one lot works out to ₹14,820.
How many lots can a retail investor apply for in the Symbiotec Pharmalab IPO?+
A retail application runs from 1 lot (15 shares, ₹14,820) up to 13 lots (195 shares, ₹1,92,660) — the most that fits under SEBI's ₹2 lakh retail ceiling.
What is the minimum HNI application in the Symbiotec Pharmalab IPO?+
A small-HNI (sHNI) application starts at 14 lots — 210 shares, ₹2,07,480. A big-HNI (bHNI) application starts at 68 lots — 1,020 shares, ₹10,07,760, above the ₹10 lakh boundary.
When does the Symbiotec Pharmalab IPO open and close?+
The issue opened on 24 Aug 2026 and closed on 27 Aug 2026. Dates can move — the registrar and the exchange notices are the record.
When is the Symbiotec Pharmalab IPO allotment?+
Allotment is scheduled for 28 Aug 2026. The basis of allotment is published by the registrar to the issue. BuyUnlistedShares does not accept, process or track IPO applications.
When did Symbiotec Pharmalab list?+
Listing took place on 01 Sept 2026 on NSE, BSE.
Where will Symbiotec Pharmalab be listed?+
Symbiotec Pharmalab is listed on NSE, BSE. It is a mainboard issue.
How large is the Symbiotec Pharmalab IPO?+
The issue size is ₹1757.00 Cr — a fresh issue of ₹150 cr and an offer for sale of ₹1,607 cr. Figures are indicative and subject to the RHP.
What is the difference between the fresh issue and the offer for sale in the Symbiotec Pharmalab IPO?+
Money raised through the fresh issue goes to the company, which spends it on the purposes set out in the offer document. Money raised through the offer for sale goes to the shareholders who are selling, not to the company. That is a fact about how the issue is structured, not a view on it.
How was the Symbiotec Pharmalab IPO subscribed?+
The issue was subscribed 75.08× overall. By category: qib 181.2×, nii 77.56×, small hni 58.01×, big hni 87.34×, retail 13.69×. Subscription figures are as reported by the exchanges.
At what price did Symbiotec Pharmalab list?+
Symbiotec Pharmalab listed at ₹988, +0% against the issue price.
Who is the registrar for the Symbiotec Pharmalab IPO?+
The registrar to the issue is MUFG Intime India Pvt.Ltd. (022-49186000), symbiotecpharmalab.ipo@in.mpms.mufg.com.
Where can I check the Symbiotec Pharmalab IPO allotment status?+
Allotment status is published by the registrar on its own official portal: https://in.mpms.mufg.com/Initial_Offer/public-issues.html. Use the registrar's site directly — BuyUnlistedShares does not ask for PAN, application numbers or any other applicant detail.